journal
MENU ▼
Read by QxMD icon Read
search

Lancet Diabetes & Endocrinology

journal
https://read.qxmd.com/read/30744946/integrating-sex-and-gender-considerations-in-research-educating-the-scientific-workforce
#1
Judith G Regensteiner, Anne M Libby, Rachel Huxley, Janine Austin Clayton
No abstract text is available yet for this article.
February 7, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30738784/obesity-and-sustainability-in-transition
#2
EDITORIAL
The Lancet Diabetes Endocrinology
No abstract text is available yet for this article.
February 6, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30737180/mummified-proportionate-dwarfs-from-the-valley-of-the-kings
#3
LETTER
Sabrina Meyer, Francesco M Galassi, Thomas Böni, Roger Seiler, Susanne Bickel, Frank Rühli
No abstract text is available yet for this article.
February 5, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30737179/diabetes-prevention-and-lifestyle-intervention-in-resource-limited-settings
#4
Thirunavukkarasu Sathish
No abstract text is available yet for this article.
February 5, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30733183/correction-to-lancet-diabetes-endocrinol-2018-published-online-dec-19-https-doi-org-10-1016-s2213-8587-18-30263-8
#5
(no author information available yet)
No abstract text is available yet for this article.
February 4, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30733182/community-groups-or-mobile-phone-messaging-to-prevent-and-control-type-2-diabetes-and-intermediate-hyperglycaemia-in-bangladesh-dmagic-a-cluster-randomised-controlled-trial
#6
Edward Fottrell, Naveed Ahmed, Joanna Morrison, Abdul Kuddus, Sanjit Kumer Shaha, Carina King, Hannah Jennings, Kohenour Akter, Tasmin Nahar, Hassan Haghparast-Bidgoli, A K Azad Khan, Anthony Costello, Kishwar Azad
BACKGROUND: Strategies are needed to prevent and control type 2 diabetes and intermediate hyperglycaemia, which together affect roughly a third of adults in Bangladesh. We aimed to assess the effects of mHealth and community mobilisation on the prevalence of intermediate hyperglycaemia and diabetes among the general adult population in rural Bangladesh, and to assess the effect of these interventions on the incidence of type 2 diabetes among people with intermediate hyperglycaemia within the study population...
February 4, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30704950/the-obesity-transition-stages-of-the-global-epidemic
#7
REVIEW
Lindsay M Jaacks, Stefanie Vandevijvere, An Pan, Craig J McGowan, Chelsea Wallace, Fumiaki Imamura, Dariush Mozaffarian, Boyd Swinburn, Majid Ezzati
The global prevalence of obesity has increased substantially over the past 40 years, from less than 1% in 1975, to 6-8% in 2016, among girls and boys, and from 3% to 11% among men and from 6% to 15% among women over the same time period. Our aim was to consolidate the evidence on the epidemiology of obesity into a conceptual model of the so-called obesity transition. We used illustrative examples from the 30 most populous countries, representing 77·5% of the world's population to propose a four stage model...
January 28, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30679095/efficacy-and-safety-of-oral-basal-insulin-versus-subcutaneous-insulin-glargine-in-type-2-diabetes-a-randomised-double-blind-phase-2-trial
#8
Inge B Halberg, Karsten Lyby, Karsten Wassermann, Tim Heise, Eric Zijlstra, Leona Plum-Mörschel
BACKGROUND: Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. METHODS: This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequately controlled on metformin monotherapy or combined with other oral antidiabetic drugs (HbA1c 7·0-10·0%; BMI 25·0-40·0 kg/m2 ), were randomly assigned (1:1) to receive once-daily I338 plus subcutaneous placebo (I338 group) or once-daily IGlar plus oral placebo (IGlar group)...
January 21, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30679094/oral-insulin-time-to-rewrite-the-textbooks
#9
Chantal Mathieu
No abstract text is available yet for this article.
January 21, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30660596/careful-investigation-of-a-rare-disease-insights-into-multiple-endocrine-neoplasia-type-2b
#10
Maya B Lodish
No abstract text is available yet for this article.
January 16, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30660595/natural-history-treatment-and-long-term-follow-up-of-patients-with-multiple-endocrine-neoplasia-type-2b-an-international-multicentre-retrospective-study
#11
Frederic Castinetti, Steven G Waguespack, Andreas Machens, Shinya Uchino, Kornelia Lazaar, Gabriella Sanso, Tobias Else, Sarka Dvorakova, Xiao Ping Qi, Rossella Elisei, Ana Luisa Maia, John Glod, Delmar Muniz Lourenço, Nuria Valdes, Jes Mathiesen, Nelson Wohllk, Tushar R Bandgar, Delphine Drui, Marta Korbonits, Maralyn R Druce, Caroline Brain, Tom Kurzawinski, Atila Patocs, Maria Joao Bugalho, Andre Lacroix, Philippe Caron, Patricia Fainstein-Day, Francoise Borson Chazot, Marc Klein, Thera P Links, Claudio Letizia, Laura Fugazzola, Olivier Chabre, Letizia Canu, Regis Cohen, Antoine Tabarin, Anita Spehar Uroic, Dominique Maiter, Sandrine Laboureau, Caterina Mian, Mariola Peczkowska, Frederic Sebag, Thierry Brue, Delphine Mirebeau-Prunier, Laurence Leclerc, Birke Bausch, Amandine Berdelou, Akihiro Sukurai, Petr Vlcek, Jolanta Krajewska, Marta Barontini, Carla Vaz Ferreira Vargas, Laura Valerio, Lucieli Ceolin, Srivandana Akshintala, Ana Hoff, Christian Godballe, Barbara Jarzab, Camilo Jimenez, Charis Eng, Tsuneo Imai, Martin Schlumberger, Elizabeth Grubbs, Henning Dralle, Hartmut P Neumann, Eric Baudin
BACKGROUND: Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. METHODS: This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions...
January 16, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30658909/low-carbohydrate-diets-in-type-2-diabetes
#12
Jeannie Tay, Martin I de Bock, Elizabeth J Mayer-Davis
No abstract text is available yet for this article.
January 15, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30638857/hope-for-patients-with-x-linked-hypophosphataemia
#13
John M Pettifor
No abstract text is available yet for this article.
January 9, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30638856/efficacy-and-safety-of-burosumab-in-children-aged-1-4-years-with-x-linked-hypophosphataemia-a-multicentre-open-label-phase-2-trial
#14
Michael P Whyte, Thomas O Carpenter, Gary S Gottesman, Meng Mao, Alison Skrinar, Javier San Martin, Erik A Imel
BACKGROUND: Children with X-linked hypophosphataemia have high concentrations of circulating phosphatonin fibroblast growth factor 23 (FGF23), which causes renal phosphate wasting and hypophosphataemia, rickets, skeletal deformities, and growth impairment. Burosumab, a human monoclonal antibody against FGF23, improves phosphate homoeostasis and rickets in children aged 5-12 years with X-linked hypophosphataemia. We aimed to assess the safety and efficacy of burosumab in younger children with X-linked hypophosphataemia...
January 9, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30635227/working-towards-novel-albuminuria-endpoints-in-chronic-kidney-disease
#15
Beatriz Fernandez-Fernandez, Maria Dolores Sanchez-Niño, Alberto Ortiz
No abstract text is available yet for this article.
January 8, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30635226/change-in-albuminuria-as-a-surrogate-endpoint-for-progression-of-kidney-disease-a-meta-analysis-of-treatment-effects-in-randomised-clinical-trials
#16
Hiddo J L Heerspink, Tom Greene, Hocine Tighiouart, Ron T Gansevoort, Josef Coresh, Andrew L Simon, Tak Mao Chan, Fan Fan Hou, Julia B Lewis, Francesco Locatelli, Manuel Praga, Francesco Paolo Schena, Andrew S Levey, Lesley A Inker
BACKGROUND: Change in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to support its validity is lacking. We aimed to determine the association between treatment effects on early changes in albuminuria and treatment effects on clinical endpoints and surrograte endpoints, to inform the use of albuminuria as a surrogate endpoint in future randomised controlled trials. METHODS: In this meta-analysis, we searched PubMed for publications in English from Jan 1, 1946, to Dec 15, 2016, using search terms including "chronic kidney disease", "chronic renal insufficiency", "albuminuria", "proteinuria", and "randomized controlled trial"; key inclusion criteria were quantifiable measurements of albuminuria or proteinuria at baseline and within 12 months of follow-up and information on the incidence of end-stage kidney disease...
January 8, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30635225/change-in-albuminuria-and-subsequent-risk-of-end-stage-kidney-disease-an-individual-participant-level-consortium-meta-analysis-of-observational-studies
#17
Josef Coresh, Hiddo J L Heerspink, Yingying Sang, Kunihiro Matsushita, Johan Arnlov, Brad C Astor, Corri Black, Nigel J Brunskill, Juan-Jesus Carrero, Harold I Feldman, Caroline S Fox, Lesley A Inker, Areef Ishani, Sadayoshi Ito, Simerjot Jassal, Tsuneo Konta, Kevan Polkinghorne, Solfrid Romundstad, Marit D Solbu, Nikita Stempniewicz, Benedicte Stengel, Marcello Tonelli, Mitsumasa Umesawa, Sushrut S Waikar, Chi-Pang Wen, Jack F M Wetzels, Mark Woodward, Morgan E Grams, Csaba P Kovesdy, Andrew S Levey, Ron T Gansevoort
BACKGROUND: Change in albuminuria as a surrogate endpoint for progression of chronic kidney disease is strongly supported by biological plausibility, but empirical evidence to support its validity in epidemiological studies is lacking. We aimed to assess the consistency of the association between change in albuminuria and risk of end-stage kidney disease in a large individual participant-level meta-analysis of observational studies. METHODS: In this meta-analysis, we collected individual-level data from eligible cohorts in the Chronic Kidney Disease Prognosis Consortium (CKD-PC) with data on serum creatinine and change in albuminuria and more than 50 events on outcomes of interest...
January 8, 2019: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30581081/within-trial-cost-and-1-year-cost-effectiveness-of-the-direct-counterweight-plus-weight-management-programme-to-achieve-remission-of-type-2-diabetes
#18
Yiqiao Xin, Andrew Davies, Louise McCombie, Andrew Briggs, C-Martina Messow, Eleanor Grieve, Wilma S Leslie, Roy Taylor, Michael E J Lean
No abstract text is available yet for this article.
December 20, 2018: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30579729/new-pharmacological-strategies-for-protecting-kidney-function-in-type-2-diabetes
#19
REVIEW
Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink
Type 2 diabetes is the leading cause of impaired kidney function, albuminuria, and renal replacement therapy globally, thus placing a large burden on health-care systems. Current treatment strategies rely on intensive glucose lowering, and strict blood pressure control targeting blockade of the renin-angiotensin-aldosterone system. Such approaches might slow decline in kidney function, but many patients progress to end-stage kidney failure despite optimal therapy. In recent clinical trials, new-generation glucose-lowering drug classes, the sodium-glucose co-transporter-2 inhibitors and agents that target the incretin pathway, have been shown to improve kidney outcomes in patients with type 2 diabetes...
December 19, 2018: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/30558909/asfotase-alfa-for-infants-and-young-children-with-hypophosphatasia-7-year-outcomes-of-a-single-arm-open-label-phase-2-extension-trial
#20
Michael P Whyte, Jill H Simmons, Scott Moseley, Kenji P Fujita, Nicholas Bishop, Nada J Salman, John Taylor, Dawn Phillips, Mairead McGinn, William H McAlister
BACKGROUND: Our previous phase 2, open-label study of 11 infants and young children with life-threatening perinatal or infantile hypophosphatasia showed 1 year safety and efficacy of asfotase alfa, an enzyme replacement therapy. We aimed to report the long-term outcomes over approximately 7 years of treatment. METHODS: We did a prespecified, end of study, 7 year follow-up of our single-arm, open-label, phase 2 trial in which children aged 3 years or younger with life-threatening perinatal or infantile hypophosphatasia were recruited from ten hospitals (six in the USA, two in the UK, one in Canada, and one in the United Arab Emirates)...
December 14, 2018: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"